Rhinovirus

2
Pipeline Programs
1
Companies
2
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
2
0
0
0
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Small Molecule
1100%
+ 1 programs with unclassified modality

Competitive Landscape

1 companies ranked by most advanced pipeline stage

Vaxart
VaxartSOUTH SAN FRANCISCO, CA
2 programs
2
BTA798Phase 21 trial
VapendavirPhase 2Small Molecule1 trial
Active Trials
NCT01175226CompletedEst. Mar 2012
NCT03024177Withdrawn

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
VaxartBTA798

Clinical Trials (2)

A Study of Vapendavir Treatment of Hematopoietic Stem Cell Transplant Subjects With Symptomatic Rhinovirus Infection

Phase 2Withdrawn

A Phase 2 Study of BTA798 in Asthmatic Adults With Symptomatic Human Rhinovirus Infection

Start: Aug 2010Est. completion: Mar 2012
Phase 2Completed

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

1 companies competing in this space